High school freshman Nina McDonald recalls simply running for the ball during middle school soccer practice when she felt a pop in her knee, followed by excruciating pain. As she fell to the ground, she remembers thinking she would never be able to play her favorite sport again.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cayennemedical/46933/
Based on its recent analysis of the medical imaging market, Frost & Sullivan recognizes Siemens Healthcare with the 2011 North American Frost & Sullivan Award for New Product Innovation. Siemens Healthcare’s innovative Biograph mMR is the first scanner capable of simultaneously acquiring whole-body positron emission tomography (PET) and magnetic resonance imaging (MRI) data.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/frostsullivan/51015/
With Arizona facing its share of tragedies lately – economically, politically and most recently the wildfires which have impacted thousands of residents – the community has found comfort in rallying together to celebrate the grand opening of the new Phoenix Children’s Hospital. The campus of Arizona’s only hospital 100 percent for children grew from 345 licensed beds to 465, and will ultimately house 626 licensed beds at full build-out, expected in 2013.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/phoenixchildrenshospital/50358/
New research debuted at the American Diabetes Association’s 72nd Annual Scientific Session suggests eating raisins three times a day may significantly lower postprandial (post-meal) glucose levels when compared to common alternative snacks of equal caloric value. The study was conducted at the Louisville Metabolic and Atherosclerosis Center (L-MARC) by lead researcher, Harold Bays, MD, medical director and president of L-MARC.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56845-california-raisin-marketing-board-raisins-reduce-post-meal-blood-sugar
Today’s U.S. healthcare providers face a three-pronged deluge of demands from patients, insurance companies, and the government. To successfully address these new and evolving expectations, members of the medical sector must leverage the capabilities of new wireless technologies – or fall behind their more savvy competitors.
Frost & Sullivan recently published a whitepaper, Mobile Devices and Healthcare: What’s New, What Fits, and How Do You Decide?, which examines the strengths and drawbacks of four major mobile device types – smartphones, tablets, push-to-talk communication devices, and machine-to-machine (M2M) remote medical monitoring devices. Each device category is evaluated for application in three unique environments – the hospital, physician’s office, and the patient’s home. Criteria for selecting a mobility partner are also discussed.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/frostsullivan/51532/
Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market and manufacturer of the industry's three premier brands: Thermage®, Fraxel®, and Isolaz®, is pleased to announce that it has partnered with PGA TOUR golfer Scott McCarron to raise awareness about skin protection and the Fraxel re:store® laser treatment. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin, including the removal of actinic keratoses (AK’s ) — a precancerous skin condition caused by sun exposure. Fraxel re:store treatment provides superior results for AKs on the face or other areas of the body displaying the signs of photodamage.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/solta/45388/
Men are 24 percent less likely than women to have visited the doctor within the past year, according to new data released today by the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality (AHRQ). In addition, men are about 30 percent more likely than women to be hospitalized for preventable conditions such as congestive heart failure and complications from diabetes, according to new AHRQ data.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/adcouncil/44387/
Each year in Germany between 400 and 550 people fall victim to fires. Interestingly, in most cases the actual cause of death is not the blaze itself but smoke inhalation. Two minutes of exposure to thick smoke can result in such serious lung damage that oxygen no longer reaches vital organs in sufficient quantities. Now a new mobile heart-lung machine might help to save lives in situations like these.
Sharps Compliance Corp. (NASDAQ: SMED), a leading full-service provider of cost-effective management solutions for medical waste and unused patient medications, is helping medical and other healthcare professional offices like doctors, dentists, vets, clinics, tattoo studios, and skilled nursing or assisted living facilities save time, money and the environment with a “GREEN” alternative to their traditional medical waste pick-up service.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/sharpsinc/48184/
Today, Solta Medical, Inc. (Nasdaq: SLTM), the pioneer in fractional resurfacing and non-invasive skin tightening and a global market leader in aesthetic treatments, announced the arrival of its groundbreaking Liposonix technology in the United States and Canada. Using advanced high-intensity focused ultrasound (HIFU) technology, Liposonix is a non-surgical permanent fat reduction procedure that has been clinically shown to slim down the waistline by one pant or dress size without surgery or downtime. It is indicated for non-invasive waist circumference reduction for use on both the abdomen and love handles.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54037-solta-liposonix-custom-contouring-waistline-fat-reduction
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Every day, sick children fight for life at Children’s Medical Center (www.childrens.com). At their bedsides are some of the world’s best surgeons, determined to do everything in their power to help them.
Beginning Aug. 3, “Children’s Med Dallas,” a five-part TV documentary airing on WFAA Ch. 8, will reveal behind-the-scenes stories of life at the nation’s 7th-largest pediatric hospital.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/childrens/51372/
